retatrutide gip glp-1 glucagon receptor agonist PDB-101: Molecule of the Month: Agonists The Road towards Triple Agonists:
Description
Nauck MA, Homberger E, Siegel EG, et al
108 Another retrospective study reported that in a population with T2DM and previously diagnosed MASLD/MASH, GLP-1RA is associated with a decreased incidence of hepatocellular carcinoma (HCC) and a reduced risk of hepatic decompensation events compared with other antidiabetic agents
Rosenlund, J.W
The starting dose period occupies the first 4 to 8 weeks
